Join us for an insightful journey into the world of diabetes management technology on this very special episode of Real-Time, Real Talk. Recorded live from the American Diabetes Association’s 83rd Scientific Sessions in San Diego, host Nancy Hanna is joined by Dexcom’s Cher Pastore in our very first simulcast. To explore how Dexcom and Omnipod are influencing the dynamics of diabetes technology and reshaping patient outcomes for the better, they’re joined by Dr. Viral Shah - an endocrinologist whose research into these innovative therapies has touched and improved countless lives. Across the episode, you'll discover how technological advancements are changing the game and reducing daily management burdens for people with diabetes. Hear invaluable insights from Dr. Shah on the importance of early adoption of tools and how they can prove pivotal in managing diabetes and improving glycemic control. Dr Shah examines the different barriers to technology adoption, and how fostering a pro-active conversation can help overcome them. All this, plus a sneak peek into the future of diabetes tech. Real-time real talk is intended for healthcare professionals in the US. Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G6 User Guide (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://dexcompdf.s3.us-west-2.amazonaws.com/en-us/G6-CGM-Users-Guide-new.pdf). For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G6 app or receiver before making treatment decisions. Dr. Viral Shah MD, is a paid spokesperson for Dexcom. About Hello Dexcom (https://provider.dexcom.com/prescribe-sample#block-contactus) Dexcom Provider website (https://provider.dexcom.com/) Warning: Do not use the Dexcom G7 CGM System or the Dexcom G6 System if you are on dialysis. The performance of these CGM systems has not been evaluated in this population and sensor readings may be inaccurate. Brief Safety Statement BRIEF SAFETY STATEMENT: Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom Clarity Safety Information The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. References: 1. Sue A. Brown, et al, Omnipod 5 Research Group; Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care 1 July 2021; 44 (7): 1630–1640. https://doi.org/10.2337/dc21-0172 2. Champakanath A, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Diabetes Care. 2022 Mar 1;45(3):750-753. doi: 10.2337/dc21-2004. 3. Mulinacci G, Alonso GT, Snell-Bergeon JK, Shah VN. Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes. Diabetes Technol Ther. 2019 Jan;21(1):6-10. doi: 10.1089/dia.2018.0257. 4. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=52464&ver=49&contractorName=all&sortBy=updated&bc=13 5. Davis GM, Peters AL, Bode BW, Carlson AL, Dumais B, Vienneau TE, Huyett LM, Ly TT. Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop Therapy. Diabetes Care. 2023 Apr 1;46(4):742-750. doi: 10.2337/dc22-1915. 6. Davis GM, et al. Automated Insulin Delivery with Remote Real-Time Continuous Glucose Monitoring for Hospitalized Patients with Diabetes: A Multi-Center, Single-arm, Feasibility Trial. Diabetes Technol Ther. 2023 Aug 14. doi: 10.1089/dia.2023.0304.